MBRX | tickerfilter.com

Fundamental analysis

Profitability 0%

Dept financing 9%

Liquidity 50%

Performance 0%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

-5.88%

1 Month

-48.03%

3 Months

-69.10%

6 Months

475.84%

1 Year

103.64%

2 Year

-77.71%

Key data

Stock price

$2.24

P/E Ratio

0.00

DAY RANGE

$2.24 - $2.35

EPS

-$2.41

52 WEEK RANGE

$0.25 - $7.98

52 WEEK CHANGE

$100.00

MARKET CAP

16.052 M

YIELD

N/A

SHARES OUTSTANDING

50.910 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

05-09-2025

BETA

3.70

PUBLIC FLOAT

AVERAGE 10 VOLUME

$136,210

AVERAGE 30 VOLUME

$247,647

Company detail

CEO: Walter V. Klemp
Region: US
Website: moleculin.com
Employees: 20
IPO year: 2016

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses. Its lead drug candidate is Annamycin that is in Phase 1/2 studies for the. treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. The company's flagship immune/transcription modulator is WP1066, which is in clinical trials for brain tumors and pediatric brain tumors.

MBRX - Moleculin Biotech, Inc.